Metastatic Pancreatic Cancer: Where Are We?

Overview

Journal Oncol Rev

Specialty Oncology

Date 2024 Feb 2

PMID 38304752

Authors

Abraham Hernandez-Blanquisett

Valeria Quintero-Carreno

Maria Cristina Martinez-Avila

Maria Porto

Maria Carolina Manzur-Barbur

Emiro Buendia

Affiliations

Soon will be listed here.

Abstract

Pancreatic cancer is one of the most lethal neoplasms worldwide; it is aggressive in nature and has a poor prognosis. The overall survival rate for pancreatic cancer is low. Most patients present non-specific symptoms in the advanced stages, which generally leads to late diagnosis, at which point there is no option for curative surgery. The treatment of metastatic pancreatic cancer includes systemic therapy, in some cases radiotherapy, and more recently, molecular targeted therapies, which can positively impact cancer control and improve quality of life. This review provides an overview of the molecular landscape of pancreatic cancer based on the most recent literature, as well as current treatment options for patients with metastatic pancreatic cancer.

Citing Articles

TRAIL receptor agonist TLY012 in combination with PD-1 inhibition promotes tumor regression in an immune-competent mouse model of pancreatic ductal adenocarcinoma.

Louie A, Huntington K, Lee Y, Mompoint J, Wu L, Lee S Am J Cancer Res. 2025; 15(1):286-298.

PMID: 39949937 PMC: 11815385. DOI: 10.62347/ROAT5658.

Long-Term Survival in Metastatic Pancreatic Adenocarcinoma of Intestinal Type.

Rahnea-Nita G, Rebegea L, Grigorean V, Coman I, Coman V, Plesea I J Clin Med. 2024; 13(17).

PMID: 39274247 PMC: 11396449. DOI: 10.3390/jcm13175034.

References

Sohal D, Kennedy E, Cinar P, Conroy T, Copur M, Crane C . Metastatic Pancreatic Cancer: ASCO Guideline Update. J Clin Oncol. 2020; 38(27):3217-3230. DOI: 10.1200/JCO.20.01364. View

Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y . FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19):1817-25. DOI: 10.1056/NEJMoa1011923. View

Hohla F, Hopfinger G, Romeder F, Rinnerthaler G, Bezan A, Stattner S . Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review. Int J Oncol. 2013; 44(1):319-26. DOI: 10.3892/ijo.2013.2176. View

Moss A, Morris E, Mac Mathuna P . Palliative biliary stents for obstructing pancreatic carcinoma. Cochrane Database Syst Rev. 2006; (1):CD004200. DOI: 10.1002/14651858.CD004200.pub2. View

Habermehl D, Brecht I, Debus J, Combs S . Palliative radiation therapy in patients with metastasized pancreatic cancer - description of a rare patient group. Eur J Med Res. 2014; 19:24. PMC: 4046029. DOI: 10.1186/2047-783X-19-24. View

Balsano R, Zanuso V, Pirozzi A, Rimassa L, Bozzarelli S . Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights. Curr Oncol. 2023; 30(4):3871-3885. PMC: 10136659. DOI: 10.3390/curroncol30040293. View

Pelzer U, Stieler J, Roll L, Hilbig A, Dorken B, Riess H . Second-line therapy in refractory pancreatic cancer. results of a phase II study. Onkologie. 2009; 32(3):99-102. DOI: 10.1159/000197769. View

Lambert A, Jarlier M, Gourgou Bourgade S, Conroy T . Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial. PLoS One. 2017; 12(9):e0183288. PMC: 5606928. DOI: 10.1371/journal.pone.0183288. View

Drewes A, Campbell C, Ceyhan G, Delhaye M, Garg P, Goor H . Pain in pancreatic ductal adenocarcinoma: A multidisciplinary, International guideline for optimized management. Pancreatology. 2018; 18(4):446-457. DOI: 10.1016/j.pan.2018.04.008. View

10.

Le D, Wang-Gillam A, Picozzi V, Greten T, Crocenzi T, Springett G . Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015; 33(12):1325-33. PMC: 4397277. DOI: 10.1200/JCO.2014.57.4244. View

11.

Okusaka T, Miyakawa H, Fujii H, Nakamori S, Satoh T, Hamamoto Y . Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer. J Cancer Res Clin Oncol. 2017; 143(6):1053-1059. PMC: 5427167. DOI: 10.1007/s00432-017-2349-y. View

12.

OHara M, OReilly E, Varadhachary G, Wolff R, Wainberg Z, Ko A . CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol. 2021; 22(1):118-131. DOI: 10.1016/S1470-2045(20)30532-5. View

13.

Park W, Chawla A, OReilly E . Pancreatic Cancer: A Review. JAMA. 2021; 326(9):851-862. PMC: 9363152. DOI: 10.1001/jama.2021.13027. View

14.

Coveler A, Mizrahi J, Eastman B, Apisarnthanarax S, Dalal S, McNearney T . Pancreas Cancer-Associated Pain Management. Oncologist. 2021; 26(6):e971-e982. PMC: 8176967. DOI: 10.1002/onco.13796. View

15.

Hofstatter E, Domchek S, Miron A, Garber J, Wang M, Componeschi K . PALB2 mutations in familial breast and pancreatic cancer. Fam Cancer. 2011; 10(2):225-31. PMC: 3836668. DOI: 10.1007/s10689-011-9426-1. View

16.

Sultana A, Tudur Smith C, Cunningham D, Starling N, Neoptolemos J, Ghaneh P . Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol. 2007; 25(18):2607-15. DOI: 10.1200/JCO.2006.09.2551. View

17.

Hendifar A, Larson B, Rojansky R, Guan M, Gong J, Placencio V . Pancreatic cancer 'mismatch' in Lynch syndrome. BMJ Open Gastroenterol. 2019; 6(1):e000274. PMC: 6577306. DOI: 10.1136/bmjgast-2019-000274. View

18.

Varghese A, Lowery M, Yu K, OReilly E . Current management and future directions in metastatic pancreatic adenocarcinoma. Cancer. 2016; 122(24):3765-3775. PMC: 5565512. DOI: 10.1002/cncr.30342. View

19.

Gill S, Ko Y, Cripps C, Beaudoin A, Dhesy-Thind S, Zulfiqar M . PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy. J Clin Oncol. 2016; 34(32):3914-3920. DOI: 10.1200/JCO.2016.68.5776. View

20.

Ma K, Chan A, She W, Chok K, Dai W, Tsang S . Efficacy of endoscopic self-expandable metal stent placement versus surgical bypass for inoperable pancreatic cancer-related malignant biliary obstruction: a propensity score-matched analysis. Surg Endosc. 2017; 32(2):971-976. DOI: 10.1007/s00464-017-5774-8. View